You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

215 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Adjuvant
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Apr 2023
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Apr 2023
Guidelines and Advice
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
May 2019
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Apr 2023

Pages